Back to discover

Protein / target

Myosin light chain kinase, smooth muscle

Encoded byMYLKQ15746Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
High-Quality Ligand
1
Research papers

Protein at a glance

Biological role

Myosin light chain kinase

Strongest disease association

Lymphohistiocytosis, Hemophagocytic

Via encoding gene MYLK · Genetic evidence · score 0.56

Research activity

Emerging research

1 papers · latest 2021

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC).

View complete UniProt function annotation

Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contraction via phosphorylation of myosin light chains (MLC). Also regulates actin-myosin interaction through a non-kinase activity. Phosphorylates PTK2B/PYK2 and myosin light-chains. Involved in the inflammatory response (e.g. apoptosis, vascular permeability, leukocyte diapedesis), cell motility and morphology, airway hyperreactivity and other activities relevant to asthma. Required for tonic airway smooth muscle contraction that is necessary for physiological and asthmatic airway resistance. Necessary for gastrointestinal motility. Implicated in the regulation of endothelial as well as vascular permeability, probably via the regulation of cytoskeletal rearrangements. In the nervous system it has been shown to control the growth initiation of astrocytic processes in culture and to participate in transmitter release at synapses formed between cultured sympathetic ganglion cells. Critical participant in signaling sequences that result in fibroblast apoptosis. Plays a role in the regulation of epithelial cell survival. Required for epithelial wound healing, especially during actomyosin ring contraction during purse-string wound closure. Mediates RhoA-dependent membrane blebbing. Triggers TRPC5 channel activity in a calcium-dependent signaling, by inducing its subcellular localization at the plasma membrane. Promotes cell migration (including tumor cells) and tumor metastasis. PTK2B/PYK2 activation by phosphorylation mediates ITGB2 activation and is thus essential to trigger neutrophil transmigration during acute lung injury (ALI). May regulate optic nerve head astrocyte migration. Probably involved in mitotic cytoskeletal regulation. Regulates tight junction probably by modulating ZO-1 exchange in the perijunctional actomyosin ring. Mediates burn-induced microvascular barrier injury; triggers endothelial contraction in the development of microvascular hyperpermeability by phosphorylating MLC. Essential for intestinal barrier dysfunction. Mediates Giardia spp.-mediated reduced epithelial barrier function during giardiasis intestinal infection via reorganization of cytoskeletal F-actin and tight junctional ZO-1. Necessary for hypotonicity-induced Ca(2+) entry and subsequent activation of volume-sensitive organic osmolyte/anion channels (VSOAC) in cervical cancer cells. Responsible for high proliferative ability of breast cancer cells through anti-apoptosis

Subcellular location

CytoplasmCell projection, lamellipodiumCleavage furrowCytoplasm, cytoskeleton, stress fiber
Domains and Gene Ontology detail (35)

Domains & features

Ig-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Ig-like C2-type 4Ig-like C2-type 5Ig-like C2-type 6Ig-like C2-type 7Ig-like C2-type 8Fibronectin type-IIIProtein kinaseIg-like C2-type 9

Gene Ontology

  • Cactin cytoskeleton
  • Ccleavage furrow
  • Ccytoplasm
  • Ccytosol
  • Clamellipodium
  • Cplasma membrane
  • Cstress fiber
  • Csynapse
  • Factin binding
  • FATP binding
  • Fcalmodulin binding
  • Fmetal ion binding

1914 aa · 211 kDa · 11 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Synaptic signallingUniProt · GOCell migrationUniProt · GOCell proliferation & survivalUniProtMuscle contractionUniProt · GOKinase signallingUniProt · GO
View supporting evidence

Synaptic signalling

  • ·Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contr…
  • ·synapse

Cell migration

  • ·Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contr…
  • ·positive regulation of cell migration

Cell proliferation & survival

  • ·Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contr…

Muscle contraction

  • ·Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contr…
  • ·smooth muscle contraction
  • ·tonic smooth muscle contraction

Kinase signalling

  • ·Calcium/calmodulin-dependent myosin light chain kinase implicated in smooth muscle contr…
  • ·myosin light chain kinase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MYLK

Gene-level evidence surfaced through the gene MYLK that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Lymphohistiocytosis, Hemophagocytic
0.56Moderately supported

Genetic evidence dominant · Open Targets 0.34

Neurodegenerative Diseases
0.29Preliminary

Pathway evidence dominant · Open Targets 0.44 · no direct causal or clinical evidence

View evidence synthesis (2)
Lymphohistiocytosis, HemophagocyticModerately supported
0.56
agreement 0.440.68
Genetic100%

Open Targets aggregate 0.34 · 1 independent evidence family

Neurodegenerative DiseasesPreliminary
0.29
agreement 0.060.52
Pathway100%

Open Targets aggregate 0.44 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.44
Lymphohistiocytosis, Hemophagocytic0.34

Tractability

Small moleculesEmerging

Feasibility evidence (high-quality ligand and druggable family) — no clinical-stage drug of this modality recorded.

AntibodiesEmerging

Feasibility evidence (go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (half-life data and small molecule binder) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · High-Quality LigandSM · Druggable FamilyAB · GO CC high confPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2021

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Kaminsky LW · Frontiers in immunology · 2021

Recent

IL-1β and the Intestinal Epithelial Tight Junction Barrier.

Kaminsky LW · Frontiers in immunology · 2021

Europe PMC papers linked directly to this protein.